Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) remains largely incurable despite advances.
• Proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have improved long-term outcomes.
• Treatment strategies are critical for patients with relapsed/refractory MM (RRMM).

Purpose of the Study:

• To review current therapeutic options for RRMM.
• To emphasize the importance of personalized treatment design for RRMM.
• To guide clinical decision-making in RRMM management.

Main Methods:

• Review of recent advancements in MM therapeutics.
• Analysis of novel agents including second-generation PIs and monoclonal antibodies.
• Discussion of factors influencing treatment selection for RRMM.

Main Results:

• Expanded therapeutic options for RRMM with carfilzomib, ixazomib, elotuzumab, and daratumumab.
• Identification of key factors for treatment decisions: drug effects, cytogenetics, complications, and prior treatment.
• Highlighting the need for individualized treatment plans.

Conclusions:

• Personalized treatment strategies are essential for optimizing survival and quality of life in RRMM.
• Understanding individual patient profiles is crucial for effective RRMM management.
• Integration of novel agents and patient-specific factors guides optimal therapeutic choices.